Proteomics in bone research.
Osteoporosis is prevalent among the elderly and is a major cause of bone fracture in this population. Bone integrity is maintained by the dynamic processes of bone resorption and bone formation (bone remodeling). Osteoporosis results when there is an imbalance of the two counteracting processes. Bone mineral density, measured by dual-energy x-ray absorptiometry has been the primary method to assess fracture risk for decades. Recent studies demonstrated that measurement of bone turnover markers allows for a dynamic assessment of bone remodeling, while imaging techniques, such as dual-energy x-ray absorptiometry, do not. The application of proteomics has permitted discoveries of new, sensitive, bone turnover markers, which provide unique information for clinical diagnosis and treatment of patients with bone diseases. This review summarizes the recent findings of proteomic studies on bone diseases, properties of mesenchymal stem cells with high expansion rates and osteoblast and osteoclast differentiation, with emphasis on the role of quantitative proteomics in the study of signaling dynamics, biomarkers and discovery of therapeutic targets.
Zhang
Hengwei
H
Genomics & Functional Proteomics Laboratories, Osteoporosis Research Center; Creighton University Medical Center, 601 N 30th Street, Suite 6730, Omaha, NE 68131, USA. hengweizhang@creighton.edu
Recker
Robert
R
Lee
Wai-Nang Paul
WN
Xiao
Gary Guishan
GG
D015415:Biomarkers; D001847:Bone Diseases / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D016723:Bone Remodeling; D001842:Bone and Bones / Q000737:chemistry / Q000166:cytology*; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000737:chemistry / Q000166:cytology; D010006:Osteoblasts / Q000737:chemistry / Q000166:cytology; D010010:Osteoclasts / Q000737:chemistry / Q000166:cytology; D010024:Osteoporosis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D040901:Proteomics / Q000379:methods*
D015415:Biomarkers